JP2008540529A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2008540529A5 JP2008540529A5 JP2008511195A JP2008511195A JP2008540529A5 JP 2008540529 A5 JP2008540529 A5 JP 2008540529A5 JP 2008511195 A JP2008511195 A JP 2008511195A JP 2008511195 A JP2008511195 A JP 2008511195A JP 2008540529 A5 JP2008540529 A5 JP 2008540529A5
- Authority
- JP
- Japan
- Prior art keywords
- alkyl
- fluorobenzyl
- alkylene
- chloro
- naphthyridine
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 125000000217 alkyl group Chemical group 0.000 claims 80
- 125000000984 3-chloro-4-fluorobenzyl group Chemical group [H]C1=C(F)C(Cl)=C([H])C(=C1[H])C([H])([H])* 0.000 claims 39
- 125000001424 substituent group Chemical group 0.000 claims 37
- 229910052799 carbon Inorganic materials 0.000 claims 35
- 229910052757 nitrogen Inorganic materials 0.000 claims 22
- 229910052760 oxygen Inorganic materials 0.000 claims 20
- 229910052739 hydrogen Inorganic materials 0.000 claims 19
- 150000001875 compounds Chemical class 0.000 claims 18
- 125000005842 heteroatom Chemical group 0.000 claims 14
- 229910052736 halogen Inorganic materials 0.000 claims 13
- 150000002367 halogens Chemical class 0.000 claims 13
- 125000000623 heterocyclic group Chemical group 0.000 claims 13
- 150000003839 salts Chemical class 0.000 claims 13
- 125000000171 (C1-C6) haloalkyl group Chemical group 0.000 claims 10
- 229910052717 sulfur Inorganic materials 0.000 claims 10
- 125000003161 (C1-C6) alkylene group Chemical group 0.000 claims 9
- 101100112680 Ostreococcus tauri CycD gene Proteins 0.000 claims 9
- 229920006395 saturated elastomer Polymers 0.000 claims 9
- -1 O—C 1-6 haloalkyl Chemical group 0.000 claims 7
- 125000004434 sulfur atom Chemical group 0.000 claims 6
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims 5
- 125000003118 aryl group Chemical group 0.000 claims 5
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims 5
- 125000004433 nitrogen atom Chemical group N* 0.000 claims 5
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 5
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims 4
- 101100273648 Mus musculus Ccna2 gene Proteins 0.000 claims 4
- 150000001721 carbon Chemical group 0.000 claims 4
- 125000004430 oxygen atom Chemical group O* 0.000 claims 4
- 230000002265 prevention Effects 0.000 claims 4
- 125000004765 (C1-C4) haloalkyl group Chemical group 0.000 claims 3
- 125000004176 4-fluorobenzyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1F)C([H])([H])* 0.000 claims 3
- 208000030507 AIDS Diseases 0.000 claims 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 claims 3
- 102100024170 Cyclin-C Human genes 0.000 claims 3
- 208000031886 HIV Infections Diseases 0.000 claims 3
- 208000037357 HIV infectious disease Diseases 0.000 claims 3
- 101000980770 Homo sapiens Cyclin-C Proteins 0.000 claims 3
- 102100034184 Macrophage scavenger receptor types I and II Human genes 0.000 claims 3
- 101710134306 Macrophage scavenger receptor types I and II Proteins 0.000 claims 3
- 208000033519 human immunodeficiency virus infectious disease Diseases 0.000 claims 3
- 125000004029 hydroxymethyl group Chemical group [H]OC([H])([H])* 0.000 claims 3
- 239000008194 pharmaceutical composition Substances 0.000 claims 3
- 125000006552 (C3-C8) cycloalkyl group Chemical group 0.000 claims 2
- FLBAYUMRQUHISI-UHFFFAOYSA-N 1,8-naphthyridine Chemical group N1=CC=CC2=CC=CN=C21 FLBAYUMRQUHISI-UHFFFAOYSA-N 0.000 claims 2
- DLFVBJFMPXGRIB-UHFFFAOYSA-N Acetamide Chemical compound CC(N)=O DLFVBJFMPXGRIB-UHFFFAOYSA-N 0.000 claims 2
- 101100059444 Mus musculus Ccnb1 gene Proteins 0.000 claims 2
- 125000002619 bicyclic group Chemical group 0.000 claims 2
- 125000002618 bicyclic heterocycle group Chemical group 0.000 claims 2
- 229910052794 bromium Inorganic materials 0.000 claims 2
- 229910052801 chlorine Inorganic materials 0.000 claims 2
- 229910052731 fluorine Inorganic materials 0.000 claims 2
- 125000001072 heteroaryl group Chemical group 0.000 claims 2
- 125000001624 naphthyl group Chemical group 0.000 claims 2
- KJMFJXVYDUAQLO-UHFFFAOYSA-N 10-[(3-chloro-4-fluorophenyl)methyl]-8-hydroxy-2,3,4,5,11,12-hexahydro-[1,4]diazepino[2,1-a][2,6]naphthyridine-1,7,9-trione Chemical compound C1CC2=C3C(=O)NCCCN3C(=O)C(O)=C2C(=O)N1CC1=CC=C(F)C(Cl)=C1 KJMFJXVYDUAQLO-UHFFFAOYSA-N 0.000 claims 1
- WDYNPHCCPGTIME-UHFFFAOYSA-N 10-[(3-chloro-4-fluorophenyl)methyl]-8-hydroxy-2-methyl-4,5,11,12-tetrahydro-3h-[1,4]diazepino[2,1-a][2,6]naphthyridine-1,7,9-trione Chemical compound O=C1N(C)CCCN(C(C(O)=C2C3=O)=O)C1=C2CCN3CC1=CC=C(F)C(Cl)=C1 WDYNPHCCPGTIME-UHFFFAOYSA-N 0.000 claims 1
- PHJWODCRYGHJFY-UHFFFAOYSA-N 2-[8-[(3-chloro-4-fluorophenyl)methyl]-6-hydroxy-3,3-dimethyl-2,5,7-trioxo-9,10-dihydroimidazo[2,1-a][2,6]naphthyridin-1-yl]-n,n-dimethylacetamide Chemical compound CN(C)C(=O)CN1C(=O)C(C)(C)N(C(C(O)=C2C3=O)=O)C1=C2CCN3CC1=CC=C(F)C(Cl)=C1 PHJWODCRYGHJFY-UHFFFAOYSA-N 0.000 claims 1
- AXTOZJLJQCJTKW-UHFFFAOYSA-N 2-[8-[(3-chloro-4-fluorophenyl)methyl]-6-hydroxy-3,3-dimethyl-2,5,7-trioxo-9,10-dihydroimidazo[2,1-a][2,6]naphthyridin-1-yl]-n-methylacetamide Chemical compound CNC(=O)CN1C(=O)C(C)(C)N(C(C(O)=C2C3=O)=O)C1=C2CCN3CC1=CC=C(F)C(Cl)=C1 AXTOZJLJQCJTKW-UHFFFAOYSA-N 0.000 claims 1
- IETZOOBCERHNOP-UHFFFAOYSA-N 2-[8-[(3-chloro-4-fluorophenyl)methyl]-6-hydroxy-3,3-dimethyl-2,5,7-trioxo-9,10-dihydroimidazo[2,1-a][2,6]naphthyridin-1-yl]ethyl acetate Chemical compound CC(=O)OCCN1C(=O)C(C)(C)N(C(C(O)=C2C3=O)=O)C1=C2CCN3CC1=CC=C(F)C(Cl)=C1 IETZOOBCERHNOP-UHFFFAOYSA-N 0.000 claims 1
- 125000000022 2-aminoethyl group Chemical group [H]C([*])([H])C([H])([H])N([H])[H] 0.000 claims 1
- 125000000954 2-hydroxyethyl group Chemical group [H]C([*])([H])C([H])([H])O[H] 0.000 claims 1
- SBNROQXOGSUZDD-UHFFFAOYSA-N 3-[8-[(3-chloro-4-fluorophenyl)methyl]-6-hydroxy-3,3-dimethyl-2,5,7-trioxo-9,10-dihydroimidazo[2,1-a][2,6]naphthyridin-1-yl]propyl acetate Chemical compound CC(=O)OCCCN1C(=O)C(C)(C)N(C(C(O)=C2C3=O)=O)C1=C2CCN3CC1=CC=C(F)C(Cl)=C1 SBNROQXOGSUZDD-UHFFFAOYSA-N 0.000 claims 1
- QOXOZONBQWIKDA-UHFFFAOYSA-N 3-hydroxypropyl Chemical group [CH2]CCO QOXOZONBQWIKDA-UHFFFAOYSA-N 0.000 claims 1
- RJGWZDLMIWKKQV-UHFFFAOYSA-N 4-[8-[(3-chloro-4-fluorophenyl)methyl]-6-hydroxy-3,3-dimethyl-2,5,7-trioxo-9,10-dihydroimidazo[2,1-a][2,6]naphthyridin-1-yl]butyl acetate Chemical compound CC(=O)OCCCCN1C(=O)C(C)(C)N(C(C(O)=C2C3=O)=O)C1=C2CCN3CC1=CC=C(F)C(Cl)=C1 RJGWZDLMIWKKQV-UHFFFAOYSA-N 0.000 claims 1
- LMEPDNBPERJOHP-UHFFFAOYSA-N 8-[(3-chloro-4-fluorophenyl)methyl]-6-hydroxy-1,3,3-trimethyl-9,10-dihydroimidazo[2,1-a][2,6]naphthyridine-2,5,7-trione Chemical compound CN1C(=O)C(C)(C)N(C(C(O)=C2C3=O)=O)C1=C2CCN3CC1=CC=C(F)C(Cl)=C1 LMEPDNBPERJOHP-UHFFFAOYSA-N 0.000 claims 1
- QKQKSLVOYMBXPY-UHFFFAOYSA-N 8-[(3-chloro-4-fluorophenyl)methyl]-6-hydroxy-1,3-bis(2-hydroxyethyl)-3-methyl-9,10-dihydroimidazo[2,1-a][2,6]naphthyridine-2,5,7-trione Chemical compound O=C1C2=C(O)C(=O)N3C(C)(CCO)C(=O)N(CCO)C3=C2CCN1CC1=CC=C(F)C(Cl)=C1 QKQKSLVOYMBXPY-UHFFFAOYSA-N 0.000 claims 1
- KCUQRILFJHPBSZ-UHFFFAOYSA-N 8-[(3-chloro-4-fluorophenyl)methyl]-6-hydroxy-1,3-dimethyl-9,10-dihydro-3h-imidazo[2,1-a][2,6]naphthyridine-2,5,7-trione Chemical compound O=C1C2=C(O)C(=O)N3C(C)C(=O)N(C)C3=C2CCN1CC1=CC=C(F)C(Cl)=C1 KCUQRILFJHPBSZ-UHFFFAOYSA-N 0.000 claims 1
- KUHSCLQNVWLBNL-UHFFFAOYSA-N 8-[(3-chloro-4-fluorophenyl)methyl]-6-hydroxy-1-(2-hydroxyethyl)-3,3-dimethyl-9,10-dihydroimidazo[2,1-a][2,6]naphthyridine-2,5,7-trione Chemical compound O=C1C2=C(O)C(=O)N3C(C)(C)C(=O)N(CCO)C3=C2CCN1CC1=CC=C(F)C(Cl)=C1 KUHSCLQNVWLBNL-UHFFFAOYSA-N 0.000 claims 1
- DNSRMBACOLYENY-UHFFFAOYSA-N 8-[(3-chloro-4-fluorophenyl)methyl]-6-hydroxy-1-(4-hydroxybutyl)-3,3-dimethyl-9,10-dihydroimidazo[2,1-a][2,6]naphthyridine-2,5,7-trione Chemical compound O=C1C2=C(O)C(=O)N3C(C)(C)C(=O)N(CCCCO)C3=C2CCN1CC1=CC=C(F)C(Cl)=C1 DNSRMBACOLYENY-UHFFFAOYSA-N 0.000 claims 1
- JEMFEHUQWQPYJA-UHFFFAOYSA-N 9-[(3-chloro-4-fluorophenyl)methyl]-7-hydroxy-2-methyl-3,4,10,11-tetrahydropyrazino[2,1-a][2,6]naphthyridine-1,6,8-trione Chemical compound O=C1N(C)CCN(C(C(O)=C2C3=O)=O)C1=C2CCN3CC1=CC=C(F)C(Cl)=C1 JEMFEHUQWQPYJA-UHFFFAOYSA-N 0.000 claims 1
- CJPDVCLBMOUAFW-UHFFFAOYSA-N 9-[(3-chloro-4-fluorophenyl)methyl]-7-hydroxy-3-(hydroxymethyl)-3,4,10,11-tetrahydro-[1,4]oxazino[3,4-a][2,6]naphthyridine-1,6,8-trione Chemical compound O=C1OC(CO)CN(C(C(O)=C2C3=O)=O)C1=C2CCN3CC1=CC=C(F)C(Cl)=C1 CJPDVCLBMOUAFW-UHFFFAOYSA-N 0.000 claims 1
- 108010002459 HIV Integrase Proteins 0.000 claims 1
- 229940099797 HIV integrase inhibitor Drugs 0.000 claims 1
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 claims 1
- WJVSDIOPTZLQGD-UHFFFAOYSA-N O=C1C2=C(O)C(=O)N3C(C)CCCN(CCO)C(=O)C3=C2CCN1CC1=CC=C(F)C(Cl)=C1 Chemical compound O=C1C2=C(O)C(=O)N3C(C)CCCN(CCO)C(=O)C3=C2CCN1CC1=CC=C(F)C(Cl)=C1 WJVSDIOPTZLQGD-UHFFFAOYSA-N 0.000 claims 1
- PYKUFEVIHVIHCL-UHFFFAOYSA-N O=C1N(CCNS(=O)(=O)C)CCCCN(C(C(O)=C2C3=O)=O)C1=C2CCN3CC1=CC=C(F)C(Cl)=C1 Chemical compound O=C1N(CCNS(=O)(=O)C)CCCCN(C(C(O)=C2C3=O)=O)C1=C2CCN3CC1=CC=C(F)C(Cl)=C1 PYKUFEVIHVIHCL-UHFFFAOYSA-N 0.000 claims 1
- UHFSVUMDVMJADE-UHFFFAOYSA-N [9-[(3-chloro-4-fluorophenyl)methyl]-7-hydroxy-1,6,8-trioxo-3,4,10,11-tetrahydro-[1,4]oxazino[3,4-a][2,6]naphthyridin-3-yl]methyl acetate Chemical compound O=C1OC(COC(=O)C)CN(C(C(O)=C2C3=O)=O)C1=C2CCN3CC1=CC=C(F)C(Cl)=C1 UHFSVUMDVMJADE-UHFFFAOYSA-N 0.000 claims 1
- 125000000738 acetamido group Chemical group [H]C([H])([H])C(=O)N([H])[*] 0.000 claims 1
- 125000003668 acetyloxy group Chemical group [H]C([H])([H])C(=O)O[*] 0.000 claims 1
- 239000003795 chemical substances by application Substances 0.000 claims 1
- 125000004122 cyclic group Chemical group 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 239000003084 hiv integrase inhibitor Substances 0.000 claims 1
- 125000002962 imidazol-1-yl group Chemical group [*]N1C([H])=NC([H])=C1[H] 0.000 claims 1
- 230000002401 inhibitory effect Effects 0.000 claims 1
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims 1
- 125000006574 non-aromatic ring group Chemical group 0.000 claims 1
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US67943105P | 2005-05-10 | 2005-05-10 | |
| US60/679,431 | 2005-05-10 | ||
| PCT/US2006/017369 WO2006121831A2 (en) | 2005-05-10 | 2006-05-05 | Hiv integrase inhibitors |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2008540529A JP2008540529A (ja) | 2008-11-20 |
| JP2008540529A5 true JP2008540529A5 (enExample) | 2009-06-18 |
| JP4982482B2 JP4982482B2 (ja) | 2012-07-25 |
Family
ID=37397115
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2008511195A Expired - Fee Related JP4982482B2 (ja) | 2005-05-10 | 2006-05-05 | Ｈｉｖインテグラ−ゼ阻害剤 |
Country Status (7)
| Country | Link |
|---|---|
| US (4) | US7741315B2 (enExample) |
| EP (1) | EP1881825B1 (enExample) |
| JP (1) | JP4982482B2 (enExample) |
| AU (1) | AU2006244424B2 (enExample) |
| CA (1) | CA2607151C (enExample) |
| TW (1) | TW200819126A (enExample) |
| WO (1) | WO2006121831A2 (enExample) |
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2007528396A (ja) | 2004-03-09 | 2007-10-11 | メルク エンド カムパニー インコーポレーテッド | Ｈｉｖインテグラーゼ阻害薬 |
| EP1725556A1 (en) | 2004-03-09 | 2006-11-29 | Merck & Co., Inc. | Hiv integrase inhibitors |
| JP2007528394A (ja) * | 2004-03-09 | 2007-10-11 | メルク エンド カムパニー インコーポレーテッド | Ｈｉｖインテグラーゼ阻害薬 |
| US7897592B2 (en) | 2005-11-15 | 2011-03-01 | Bristol-Myers Squibb Company | HIV integrase inhibitors |
| US7902182B2 (en) | 2005-11-16 | 2011-03-08 | Bristol-Myers Squibb Company | HIV integrase inhibitors |
| US8039458B2 (en) | 2005-11-17 | 2011-10-18 | Bristol-Myers Squibb Company | HIV integrase inhibitors |
| CA2645551C (en) | 2006-03-16 | 2016-06-28 | Renovis, Inc. | Bicycloheteroaryl compounds as p2x7 modulators and uses thereof |
| US7897593B2 (en) | 2006-05-30 | 2011-03-01 | Bristol-Myers Squibb Company | HIV integrase inhibitors |
| US7893055B2 (en) | 2006-06-28 | 2011-02-22 | Bristol-Myers Squibb Company | HIV integrase inhibitors |
| AU2007313293A1 (en) * | 2006-10-18 | 2008-04-24 | Merck & Co., Inc. | HIV integrase inhibitors |
| US7763630B2 (en) | 2007-06-06 | 2010-07-27 | Bristol-Myers Squibb Company | HIV integrase inhibitors |
| US8129398B2 (en) | 2008-03-19 | 2012-03-06 | Bristol-Myers Squibb Company | HIV integrase inhibitors |
| US8143244B2 (en) | 2009-02-26 | 2012-03-27 | Bristol-Myers Squibb Company | Cyclopropyl fused indolobenzazepine HCV NS5B inhibitors |
| US8383639B2 (en) | 2009-10-15 | 2013-02-26 | Bristol-Myers Squibb Company | HIV integrase inhibitors |
| US8283366B2 (en) | 2010-01-22 | 2012-10-09 | Ambrilia Biopharma, Inc. | Derivatives of pyridoxine for inhibiting HIV integrase |
| CA2814703A1 (en) * | 2010-10-29 | 2012-05-03 | Merck Sharp & Dohme Corp. | Hiv integrase inhibitors |
| WO2012131539A1 (en) | 2011-03-31 | 2012-10-04 | Pfizer Inc. | Novel bicyclic pyridinones |
| UA110688C2 (uk) | 2012-09-21 | 2016-01-25 | Пфайзер Інк. | Біциклічні піридинони |
| WO2014172188A2 (en) | 2013-04-16 | 2014-10-23 | Merck Sharp & Dohme Corp. | 4-pyridone derivative compounds and uses thereof as hiv integrase inhibitors |
| TN2017000342A1 (en) | 2015-02-03 | 2019-01-16 | Pfizer | Novel cyclopropabenzofuranyl pyridopyrazinediones |
Family Cites Families (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2329134A1 (en) * | 1998-06-03 | 1999-12-09 | David L. Clark | Hiv integrase inhibitors |
| US6380249B1 (en) * | 1998-06-03 | 2002-04-30 | Merck & Co., Inc. | HIV integrase inhibitors |
| US6306891B1 (en) * | 1998-06-03 | 2001-10-23 | Merck & Co., Inc. | HIV integrase inhibitors |
| US6262055B1 (en) * | 1998-06-03 | 2001-07-17 | Merck & Co., Inc. | HIV integrase inhibitors |
| JP2003503386A (ja) * | 1999-06-25 | 2003-01-28 | メルク エンド カムパニー インコーポレーテッド | １−（芳香族またはヘテロ芳香族置換）−３−（ヘテロ芳香族置換）−１，３−プロパンジオン類およびそれの使用 |
| DE60124577T2 (de) * | 2000-10-12 | 2007-09-27 | Merck & Co., Inc. | Aza- und polyaza-naphthalenylcarbonsäureamide als hiv-integrase-hemmer |
| WO2002036734A2 (en) * | 2000-10-12 | 2002-05-10 | Merck & Co., Inc. | Aza-and polyaza-naphthalenyl ketones useful as hiv integrase inhibitors |
| AU1532802A (en) * | 2000-10-12 | 2002-04-22 | Merck & Co Inc | Aza- and polyaza-naphthalenyl-carboxamides useful as hiv integrase inhibitors |
| ATE430745T1 (de) * | 2000-10-12 | 2009-05-15 | Merck & Co Inc | Aza- und polyaza naphthalenyl karboxamide als inhibitoren der hiv-integrase |
| DK3042894T1 (da) * | 2001-08-10 | 2016-11-07 | Shionogi & Co | Antiviralt middel |
| SI1441734T1 (sl) * | 2001-10-26 | 2007-08-31 | Angeletti P Ist Richerche Bio | Dihidropirimidin karboksamidni inhibitorji HIV-integraze |
| DE60209381T2 (de) * | 2001-10-26 | 2006-10-05 | Istituto Di Ricerche Di Biologia Molecolare P. Angeletti S.P.A. | N-substituierte hydroxypyrimidinoncarboxamid-hemmer der hiv-integrase |
| ES2291642T3 (es) * | 2002-01-17 | 2008-03-01 | MERCK & CO., INC. | Hidroxinaftiridinoncarboxamidas utiles como inhibidores de la integrasa de vih. |
| AU2003248872A1 (en) * | 2002-07-09 | 2004-01-23 | Bristol-Myers Squibb Company | Hiv integrase inhibitors |
| PA8586801A1 (es) * | 2002-10-31 | 2005-02-04 | Pfizer | Inhibidores de hiv-integrasa, composiciones farmaceuticas y metodos para su uso |
| TW200510425A (en) * | 2003-08-13 | 2005-03-16 | Japan Tobacco Inc | Nitrogen-containing fused ring compound and use thereof as HIV integrase inhibitor |
| EP1725556A1 (en) * | 2004-03-09 | 2006-11-29 | Merck & Co., Inc. | Hiv integrase inhibitors |
| JP2007528396A (ja) | 2004-03-09 | 2007-10-11 | メルク エンド カムパニー インコーポレーテッド | Ｈｉｖインテグラーゼ阻害薬 |
| CA2557926A1 (en) * | 2004-03-09 | 2005-09-22 | Monica Donghi | Hiv integrase inhibitors |
| PT1874117E (pt) | 2005-04-28 | 2013-10-17 | Shionogi & Co | Derivado policíclico de carbamoílpiridona possuindo actividade inibidora de hiv-integrasse |
-
2006
- 2006-05-05 CA CA2607151A patent/CA2607151C/en not_active Expired - Fee Related
- 2006-05-05 AU AU2006244424A patent/AU2006244424B2/en not_active Ceased
- 2006-05-05 US US11/920,032 patent/US7741315B2/en not_active Expired - Fee Related
- 2006-05-05 EP EP06759135.4A patent/EP1881825B1/en not_active Expired - Lifetime
- 2006-05-05 WO PCT/US2006/017369 patent/WO2006121831A2/en not_active Ceased
- 2006-05-05 JP JP2008511195A patent/JP4982482B2/ja not_active Expired - Fee Related
- 2006-10-27 TW TW095139679A patent/TW200819126A/zh unknown
-
2010
- 2010-04-15 US US12/760,638 patent/US7968564B2/en not_active Expired - Fee Related
-
2011
- 2011-05-13 US US13/107,512 patent/US8293731B2/en not_active Expired - Fee Related
-
2012
- 2012-09-07 US US13/606,929 patent/US20130178468A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA2607151A1 (en) | Hiv integrase inhibitors | |
| JP2010522750A5 (enExample) | ||
| JP2024532735A5 (enExample) | ||
| JP2025535045A (ja) | Ｋｒａｓ ｇ１２ｃ変異タンパク質の複素環阻害剤及びその使用 | |
| JP2007528379A5 (enExample) | ||
| RU2010136057A (ru) | (ДИГИДРО)ПИРРОЛО[2,1-a]ИЗОХИНОЛИНЫ | |
| JP2017524702A5 (enExample) | ||
| RU2011117412A (ru) | Трициклические оксазолидиноновые антибиотические соединения | |
| JP2013537210A5 (enExample) | ||
| RU2017135467A (ru) | Комбинированное лечение агонистом толл-подобного рецептора (tlr7) и ингибитором сборки капсида вируса гепатита в | |
| JP2014513139A5 (enExample) | ||
| RU2012145237A (ru) | Производные арилэтинила | |
| JP2014528479A5 (enExample) | ||
| CA2491506A1 (en) | N-aryl diazaspiracyclic compounds and methods of preparation and use thereof | |
| RU2007147413A (ru) | Аминопиперидинхинолины и их азаизостерические аналоги с антибактериальной активностью | |
| JP2007528396A5 (enExample) | ||
| JP2007523183A5 (enExample) | ||
| JP2011506466A5 (enExample) | ||
| JP2006513200A5 (enExample) | ||
| RU2006105721A (ru) | Комбинация антагониста рецептора mgiur2 и ингибитора фермента ache для лечения острых и/или хронических неврологических заболеваний | |
| JP2019504102A5 (enExample) | ||
| JP2006511595A5 (enExample) | ||
| CA2833962A1 (en) | Combination of a phosphatidylinositol-3-kinase (pi3k) inhibitor and a mtor inhibitor | |
| JP2024542949A5 (enExample) | ||
| AU2011240001B2 (en) | Combination of organic compounds |